Harshika Sarbajna recently assumed the role of Global Head of Anti-Infectives, Oral, for Sandoz (a Novartis Division) and is responsible for ensuring sustainable access to and promoting proper use of anti-infectives.
In this role, she is also spearheading the Sandoz/Novartis wide AMR Stewardship program, bringing together stakeholders both inside and outside the organization. She is committed to driving practical, scalable solutions that deliver meaningful impact in combating AMR.
She previously served as the Global Head of Strategy and Operations for the Biopharmaceuticals business unit within Sandoz. During Harshika’s tenure in Biopharmaceuticals, she successfully navigated a dynamic marketplace, working across functions to develop and implement a strategy that saw three positive CHMP positive opinions and two EC approvals in the last 12 months.
Prior to Sandoz, Harshika served as Head of business strategy for the biosimilars business at Dr. Reddy’s Lab, and drove growth across the portfolio in key markets including the US, Asia, Latin America and Russia. Before joining Dr. Reddy’s, she led various executive-level advisory engagements on business and growth strategy for large Corporates. Harshika began her career at Infosys, working with retail businesses across Europe and the US on their customer acquisition and retention strategy.